# Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.

> **NCT07468513** · PHASE4 · RECRUITING · sponsor: **Menzies School of Health Research** · enrollment: 100 (estimated)

## Conditions studied

- Vivax Malaria
- G6PD Deficiency

## Interventions

- **DRUG:** Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days
- **DRUG:** Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose).

## Key facts

- **NCT ID:** NCT07468513
- **Lead sponsor:** Menzies School of Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-17
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468513, "Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07468513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*